LifeMD, Inc.
LFMD
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $149.0M
$3.08
▲ +0.98%
P/E
-6.06
Mkt Cap
$149.0M
52-Wk Range
$2.56–$7.32
52-Week Range
$2.56 - $7.32
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 49.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
6 reasons
- Diversified multi-brand portfolio reducing revenue concentration risk
- Proprietary doctor-formulated products and FDA-approved medical devices creating differentiation
- Direct-to-consumer model enabling higher margins and customer data ownership
- Integrated platform combining consultations, prescriptions, diagnostics, and imaging
- Subscription-based recurring revenue model providing predictable cash flows
- Mobile-first technology platform optimized for consumer convenience and engagement
Bear Case
1 risk
- High volatility (beta 2.0). Larger-than-normal price swings expected.
Growth
Stable outlook
Premium gross margins (86%)
Value
Deep value opportunity - significant discount to Healthcare Distribution peers
Momentum
Falling
-38.6% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LFMD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 5, 2026
Reported EPS of -$0.16 vs -$0.15 consensus (-9.8% surprise). Revenue of $47.3M vs $49.2M expected (-3.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-9.8%
Revenue trend · last 8Q
—
+43%
+49%
+23%
+13%
-27%
-24%
-24%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$53.3M
$64.3M
$65.7M
$62.2M
$60.2M
$46.9M
$50.2M
$47.3M
Margins · last 8Q
Gross
92.4%
Operating
-15.1%
Profit
-16.6%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: KeyBanc · Aug 7, 2026
vs Industry
How LFMD stacks vs Medical - Healthcare Information Services
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related